跳至主要内容
临床试验/NL-OMON47623
NL-OMON47623已完成不适用

Effect of Intravenous Administration of C1-inhibitor on Inflammation and Coagulation after Bronchial Instillation of House Dust Mite Allergen and Lipopolysaccharide in Allergic Asthma Patients - CAST-study

Academisch Medisch Centrum0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • - Mild asthma patients between 18 and 45 years
  • - Allergy for house dust mite
  • - Spirometry FEV1 more than 70% of predicted value
  • - A PC20 between 1.2 * 9.6 mg/ml
  • - Stable asthma without the use of asthma medication 2 weeks prior to the study day
  • - No current smoking for at least 1 year and less than 10 pack years of smoking history
  • - No clinically significant findings during physical examination and hematological and biochemical screening
  • - Normal defecation pattern (defined as *3x/ day and *3x/week)

排除标准

  • - Relevant comorbidity, pregnancy and/or recent surgical procedures.
  • - A history of smoking within the last 12 months, or regular consumption of greater than three units of alcohol per day
  • - Exacerbation and/ or the use of asthma medication within 2 weeks before start
  • - Administration of any investigational drug within 30 days of study initiation
  • - Donation of blood within 60 days, or loss of greater than 400 ml of blood within 12 weeks of study initiation
  • - Inability to maintain stable without the use of asthma medication 2 weeks before start.
  • - History of venous or arterial thromboembolic disease

研究者

相似试验

进行中(未招募)
1 期
Effect of Intravenous Administration of C1-inhibitor on Inflammation and Coagulation after Bronchial Instillation of House Dust Mite Allergen and Lipopolysaccharide in Allergic Asthma Patients
EUCTR2014-005611-16-NLAcademic Medical Center, University of Amsterdam60
招募中
不适用
Analysis of the C1-Esterase Inhibitor at patients with COVID-19 as a biomarker for the course of the diseaseCOVID-19
DRKS00021440niversitätsklinikum Gießen und Marburg50
招募中
3 期
Intravenous and oral cyclophosphamide in membranous nephropathy
IRCT20230517058211N1Jinnah Hospital/ Allama Iqbal Medical College58
尚未招募
不适用
In vivo effects of C1-esterase inhibitor on innate immune response during endotoxemia in human.sepsisinflammation1002766510002252
NL-OMON32783niversitair Medisch Centrum Sint Radboud10
进行中(未招募)
1 期
A study of the effect of the drug C1-esterase inhibitor on the immune system in patients after administration of endotoxin.Inflammation, SIRS and endotoxemiaMedDRA version: 15.1Level: PTClassification code 10061218Term: InflammationSystem Organ Class: 10018065 - General disorders and administration site conditionsMedDRA version: 15.1Level: LLTClassification code 10060412Term: Septicaemia due to Escherichia coli (E. coli)System Organ Class: 10021881 - Infections and infestationsMedDRA version: 15.1Level: LLTClassification code 10051553Term: Complement factor C1System Organ Class: 100000004848MedDRA version: 15.1Level: PTClassification code 10040047Term: SepsisSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 15.1Level: LLTClassification code 10062357Term: SIRSSystem Organ Class: 10018065 - General disorders and administration site conditions
EUCTR2011-002222-46-NLRadboud University Nijmegen Medical Centre20